Clinical Trial

Personalized Antisense Oligonucleotide Therapy for A Single Participant With CHCHD10 ALS

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-26; most recent amendment 2026-07-09.
Trial Details
NCT Number NCT06392126
Lead Sponsor n-Lorem Foundation
Collaborators: Mayo Clinic
Conditions Amyotrophic Lateral Sclerosis
Enrollment 1 participants
Start Date 2024-04-16
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-07-13